NBOMe & Injectable opiates
NBOMe compounds, a family of potent synthetic psychedelic phenethylamines, act primarily as highly selective agonists at the 5-HT2A receptor, the primary site responsible for the hallucinogenic effects of classical psychedelics.
Unlike LSD or psilocybin, which also target this receptor but with broader activity across serotonergic subtypes, NBOMe compounds exhibit sub-nanomolar affinity and exceptional selectivity for 5-HT2A, making them among the most potent hallucinogens known. This heightened affinity facilitates intense visual and sensory distortions, but it also confers a steep dose-response curve and increased risk of toxicity.
Notably, the NBOMe series (e.g., 25I-NBOMe, 25C-NBOMe) also shows moderate activity at 5-HT2C and trace activity at dopaminergic and adrenergic receptors, which may contribute to sympathomimetic side effects such as hypertension, tachycardia, hyperthermia, and vasoconstriction.
NBOMes are not orally active and require sublingual, buccal, or nasal administration, further complicating dose accuracy, as minute differences in absorption can produce vastly different pharmacodynamic outcomes. Importantly, their action is not merely serotonergic; emerging evidence suggests that NBOMe compounds may also indirectly influence glutamatergic transmission via downstream signaling cascades, potentially accounting for their intense and sometimes dysphoric psychotropic effects.
Injectable opiates, such as heroin (diacetylmorphine) or pharmaceutical opioids like hydromorphone and morphine, act predominantly through agonism of the mu-opioid receptor (MOR), a G-protein-coupled receptor that inhibits adenylate cyclase activity, decreases intracellular cAMP levels, and ultimately reduces neuronal excitability by increasing potassium conductance and inhibiting calcium influx. This cascade results in profound analgesia, sedation, and euphoria.
At the mesolimbic level, opioids disinhibit dopaminergic neurons in the ventral tegmental area (VTA), increasing dopamine release in the nucleus accumbens, a key mechanism underlying their addictive potential. Chronic opioid use induces neuroadaptations such as receptor downregulation and changes in intracellular signaling pathways (e.g., CREB, dynorphin), leading to tolerance, dependence, and a withdrawal syndrome characterized by hyperalgesia, dysphoria, and autonomic dysfunction.
Injectable administration, particularly intravenous, produces a rapid onset of action and intense subjective effects, which enhances both the reinforcing properties and the risk of overdose, especially in poly-drug contexts.
The concurrent use of NBOMe compounds and injectable opioids represents a pharmacological juxtaposition of serotonergic overstimulation with opioid-induced central nervous system depression.
This combination is relatively underexplored but raises several mechanistic concerns. NBOMe-induced sympathomimetic activation—manifested as elevated heart rate, blood pressure, and thermogenesis—can be masked by the sedative and respiratory depressive effects of opioids, complicating clinical detection of toxic states.
Moreover, opioids suppress the pre-Bötzinger complex in the medulla, impairing respiratory drive, while NBOMe compounds, particularly at high doses, have been associated with seizures, rhabdomyolysis, and serotonin toxicity, which could exacerbate opioid-induced hypoxia or lead to unpredictable interactions at the level of cortical and subcortical brain structures. The dual burden on thermoregulatory, cardiovascular, and respiratory systems increases the risk of multi-organ failure in overdose situations.
Additionally, the psychological disinhibition and perceptual distortions induced by NBOMe may impair the user's ability to monitor or regulate opioid dosing, while opioids may blunt the intense, sometimes dysphoric, NBOMe experience, prompting redosing and increasing cumulative toxicity risk.
Case reports and toxicological analyses have documented fatal outcomes involving NBOMe compounds, often in polydrug contexts that include opioids, benzodiazepines, or stimulants. For instance, several forensic pathology studies in Europe and North America have identified NBOMe-opioid mixtures in postmortem toxicology screens, although causality is frequently confounded by polypharmacy.
In one study published in Forensic Science International, NBOMe derivatives were detected alongside opioids in cases of sudden death, highlighting the risk of additive or synergistic toxicity.
Furthermore, retrospective analyses of emergency department visits suggest that NBOMe users presenting with altered mental status or seizures sometimes report concurrent use of opioids, although controlled studies remain absent.
All things considered, we recommend avoiding this combination.
Last edited by a moderator: